3,663
Views
5
CrossRef citations to date
0
Altmetric
Review Article

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis

ORCID Icon, &
Article: 2140569 | Received 05 Apr 2022, Accepted 24 Oct 2022, Published online: 19 Jan 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Lluís Rusiñol, Elena Carmona-Rocha & Lluís Puig. (2023) Durability and long-term outcomes of biologic therapies in psoriasis. Expert Review of Clinical Immunology 0:0, pages 1-12.
Read now

Articles from other publishers (4)

Vered Abitbol, Salim Benkhalifa, Caroline Habauzit & Hubert Marotte. (2023) Navigating adalimumab biosimilars: an expert opinion. Journal of Comparative Effectiveness Research 12:11.
Crossref
Giampiero Girolomoni, Laura Savage, Paolo Gisondi, Åke Svensson, Emmanuel Mahé, Matthias Augustin & Luis Puig. (2023) Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatology and Therapy 13:10, pages 2171-2185.
Crossref
Alicia Goh, Laoise Griffin & Muriel Sadlier. (2023) Switching to biosimilars in dermatology: a patients’ perspective. Clinical and Experimental Dermatology.
Crossref
Christina Kontzias, Rithi Chandy & Steven R. Feldman. (2023) Choosing Systemic Agents for Psoriasis. Annals of Pharmacotherapy.
Crossref